HUTCHMED Highlights Savolitinib SAVANNAH Phase II, Other Data at European Lung Cancer Congress

 — SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting —

— Long-term survival benefit and safety observed in savolitinib Phase IIIb study in METex14 NSCLC —

https://www.globenewswire.com/news-release/2025/03/20/3045892/0/en/HUTCHMED-Highlights-Savolitinib-SAVANNAH-Phase-II-and-Other-Data-at-European-Lung-Cancer-Congress-2025.html